Study S002195

Pharmacological Postconditioning to Reduce Infarct Size Following Primary PCI in Patients With STEMI

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT00835848
Acronym: POSTCON II
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 100
Start: 2009-01
Primary completion: 2009-12
Lead sponsor: Copenhagen University Hospital, Rigshospitalet
Conditions: Myocardial Infarction
Interventions: DRUG:Exenatide; DRUG:Saline
Results posted: FALSE

Registered primary outcomes

Infarct size by MRI [3 months]

Linked records (3)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0025816	Protective effect of glucagon-like peptide-1 agents on reperfusion injury for acute myocardial infarction: a meta-analysis of randomized controlled trials. Huang M, Annals of medicine	2017	Systematic review	PMID 28286967 DOI	cites ClinicalTrials.gov:NCT00835848; registry reference DERIVED:28286967
R0023502	Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Lønborg J, European heart journal	2012	Randomized trial	PMID 21920963 DOI	cites ClinicalTrials.gov:NCT00835848; registry reference DERIVED:21920963
R0026946	Exenatide reduces final infarct size in patients with ST-segment-elevation myocardial infarction and short-duration of ischemia. Lønborg J, Circulation. Cardiovascular interventions	2012	Randomized trial	PMID 22496084 DOI	cites ClinicalTrials.gov:NCT00835848; registry reference DERIVED:22496084